FDA Warns About Serious Adverse Effect of AML Drug Enasidenib

The US Food and Drug Administration issued a safety warning emphasizing the importance of monitoring for differentiation syndrome in patients with acute myeloid leukemia being treated with enasidenib. This potential life-threatening adverse event can manifest as an early or late side effect, so physicians should educate patients on the signs and symptoms when starting the drug.